Literature DB >> 8368635

Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis.

G A Ellard1, M J Humphries, B W Allen.   

Abstract

Tuberculous meningitis is a very serious form of tuberculosis. In the absence of randomized controlled trials of alternative treatment regimens, its management depends on employing potent drugs that penetrate well into the cerebrospinal fluid (CSF). The penetration of isoniazid, rifampin, and streptomycin into the CSF of 27 Chinese patients was studied using fluorimetric and microbiologic procedures. Isoniazid rapidly diffused into the CSF, peak concentrations in excess of 3 mg/L, or over 30 times its minimal inhibitory concentration (MIC) against Mycobacterium tuberculosis being attained within 4 hr. In contrast, rifampin and streptomycin penetrated very slowly across the meninges, and CSF levels only slightly in excess of their MICs against M. tuberculosis were achieved. The penetration of the drugs into the CSF correlated poorly with differences in their partitioning between octanol/water and cyclohexane/water but could be predicted using a simple model based on their renal clearance rates and plasma protein binding. It is recommended that patients with tuberculous meningitis should be treated for at least 9 months with a combination of isoniazid, rifampin, and pyrazinamide, which may be supplemented in the first 2 mo with streptomycin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8368635     DOI: 10.1164/ajrccm/148.3.650

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  36 in total

Review 1.  Tuberculous meningitis.

Authors:  G Thwaites; T T Chau; N T Mai; F Drobniewski; K McAdam; J Farrar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

Review 2.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.

Authors:  Maria C Kjellsson; Laura E Via; Anne Goh; Danielle Weiner; Kang Min Low; Steven Kern; Goonaseelan Pillai; Clifton E Barry; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

4.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 5.  Central nervous system tuberculosis.

Authors:  A Cherian; S V Thomas
Journal:  Afr Health Sci       Date:  2011-03       Impact factor: 0.927

Review 6.  New agents for the treatment of drug-resistant Mycobacterium tuberculosis.

Authors:  Daniel T Hoagland; Jiuyu Liu; Robin B Lee; Richard E Lee
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

7.  A Macrophage Infection Model to Predict Drug Efficacy Against Mycobacterium Tuberculosis.

Authors:  Kaitlyn Schaaf; Virginia Hayley; Alexander Speer; Frank Wolschendorf; Michael Niederweis; Olaf Kutsch; Jim Sun
Journal:  Assay Drug Dev Technol       Date:  2016-06-21       Impact factor: 1.738

Review 8.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

9.  Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study.

Authors:  Christopher Vinnard; Carla A Winston; E Paul Wileyto; Rob Roy Macgregor; Gregory P Bisson
Journal:  BMJ       Date:  2010-09-06

Review 10.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.